Progress in the treatment of vascular complications in type 2 diabetes by finerenone in combination with RAS inhibitors/SGLT-2i

IF 2.9 3区 医学 Q3 ENDOCRINOLOGY & METABOLISM
Ruoqi Liu , Zhuomin Qu , Yizhuo Feng , Lu Bai , Xueqian Liu , Xuemei Fan , Xiaoqi Liu , Lingxia Zhao
{"title":"Progress in the treatment of vascular complications in type 2 diabetes by finerenone in combination with RAS inhibitors/SGLT-2i","authors":"Ruoqi Liu ,&nbsp;Zhuomin Qu ,&nbsp;Yizhuo Feng ,&nbsp;Lu Bai ,&nbsp;Xueqian Liu ,&nbsp;Xuemei Fan ,&nbsp;Xiaoqi Liu ,&nbsp;Lingxia Zhao","doi":"10.1016/j.jdiacomp.2025.108981","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Currently, the prevalence of diabetes is rising. Patients with diabetes often face high risks of kidney disease, cardiovascular disease, and retinal disease. Cardiovascular complications are the primary cause of morbidity and mortality in patients with type 2 diabetes mellitus. Finerenone is a novel non-steroidal mineralocorticoid receptor antagonist. Research has shown that finerenone provides renal, cardiac, and retinal protection in patients with type 2 diabetes. Currently, various drugs (angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, sodium-glucose co-transporter 2 inhibitors) are effective in treating diabetic vascular complications, but each has its limitations. Combining finerenone with RAS Inhibitors/SGLT-2i may yield better clinical outcomes.</div></div><div><h3>Methods</h3><div>This review aggregates research on the mechanisms and clinical efficacy of finerenone, RAS Inhibitors, and SGLT-2i used individually, as well as in combination, for the treatment of vascular complications in diabetes from various databases.</div></div><div><h3>Results</h3><div>This review shows that combining finerenone with RAS inhibitors/ SGLT-2 inhibitors can further reduce proteinuria, the urinary albumin-to-creatinine ratio, and the risk of hyperkalemia, slow CKD progression, reduce atherosclerosis, myocardial fibrosis, and hypertrophy, and lower the incidence of atrial fibrillation, myocardial infarction, and heart failure. It can also reduce retinal neovascularization, macular edema, and inflammation. Overall, combining can further lower the risk of complications in type 2 diabetic patients.</div></div><div><h3>Conclusions</h3><div>In summary, combining finerenone with RAS inhibitors and SGLT-2i is a promising treatment strategy. However, the molecular mechanisms and interactions are not fully understood, necessitating more basic research and clinical trials to provide evidence. Combining finerenone with existing treatments may yield better clinical outcomes.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 4","pages":"Article 108981"},"PeriodicalIF":2.9000,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of diabetes and its complications","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1056872725000340","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Currently, the prevalence of diabetes is rising. Patients with diabetes often face high risks of kidney disease, cardiovascular disease, and retinal disease. Cardiovascular complications are the primary cause of morbidity and mortality in patients with type 2 diabetes mellitus. Finerenone is a novel non-steroidal mineralocorticoid receptor antagonist. Research has shown that finerenone provides renal, cardiac, and retinal protection in patients with type 2 diabetes. Currently, various drugs (angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, sodium-glucose co-transporter 2 inhibitors) are effective in treating diabetic vascular complications, but each has its limitations. Combining finerenone with RAS Inhibitors/SGLT-2i may yield better clinical outcomes.

Methods

This review aggregates research on the mechanisms and clinical efficacy of finerenone, RAS Inhibitors, and SGLT-2i used individually, as well as in combination, for the treatment of vascular complications in diabetes from various databases.

Results

This review shows that combining finerenone with RAS inhibitors/ SGLT-2 inhibitors can further reduce proteinuria, the urinary albumin-to-creatinine ratio, and the risk of hyperkalemia, slow CKD progression, reduce atherosclerosis, myocardial fibrosis, and hypertrophy, and lower the incidence of atrial fibrillation, myocardial infarction, and heart failure. It can also reduce retinal neovascularization, macular edema, and inflammation. Overall, combining can further lower the risk of complications in type 2 diabetic patients.

Conclusions

In summary, combining finerenone with RAS inhibitors and SGLT-2i is a promising treatment strategy. However, the molecular mechanisms and interactions are not fully understood, necessitating more basic research and clinical trials to provide evidence. Combining finerenone with existing treatments may yield better clinical outcomes.
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of diabetes and its complications
Journal of diabetes and its complications 医学-内分泌学与代谢
CiteScore
5.90
自引率
3.30%
发文量
153
审稿时长
16 days
期刊介绍: Journal of Diabetes and Its Complications (JDC) is a journal for health care practitioners and researchers, that publishes original research about the pathogenesis, diagnosis and management of diabetes mellitus and its complications. JDC also publishes articles on physiological and molecular aspects of glucose homeostasis. The primary purpose of JDC is to act as a source of information usable by diabetes practitioners and researchers to increase their knowledge about mechanisms of diabetes and complications development, and promote better management of people with diabetes who are at risk for those complications. Manuscripts submitted to JDC can report any aspect of basic, translational or clinical research as well as epidemiology. Topics can range broadly from early prediabetes to late-stage complicated diabetes. Topics relevant to basic/translational reports include pancreatic islet dysfunction and insulin resistance, altered adipose tissue function in diabetes, altered neuronal control of glucose homeostasis and mechanisms of drug action. Topics relevant to diabetic complications include diabetic retinopathy, neuropathy and nephropathy; peripheral vascular disease and coronary heart disease; gastrointestinal disorders, renal failure and impotence; and hypertension and hyperlipidemia.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信